Boston Scientific
-
Saudi Ministry of Health collaborates with Boston Scientific on Walk Safe initiative to reduce diabetic amputations
The collaboration follows the signing of a Memorandum of Understanding and forms part of Saudi Arabia’s broader efforts to enhance preventive healthcare and improve outcomes for people living with chronic diseases.
-
Boston Scientific expands structural heart push with US$1.5B MiRus TAVR investment
This agreement also grants Boston Scientific an exclusive option to acquire the TAVR programme, subject to additional payments and to clinical and regulatory milestones.
-
Boston Scientific announces US88.5M R&D expansion in Galway to advance cardiovascular innovation
In addition, the investment will strengthen research into emerging treatment areas such as heart failure and renal denervation, a minimally invasive therapy for uncontrolled hypertension.
-
Boston Scientific re-enters neurovascular market with USD14.5B Penumbra deal
Penumbra shareholders will have the option to receive either USD374 in cash or 3.8721 Boston Scientific shares, with the transaction structured as approximately 73% cash and 27% stock.